Reuters logo
BRIEF-Ligand says partner Lundbeck plans to make Carnexiv commercially available in U.S. in early 2017
October 7, 2016 / 11:47 PM / a year ago

BRIEF-Ligand says partner Lundbeck plans to make Carnexiv commercially available in U.S. in early 2017

Oct 7 (Reuters) - Ligand Pharmaceuticals Inc

* Partner Lundbeck receives FDA approval of Carnexiv(tm) (carbamazepine) injection as intravenous short-term replacement therapy for certain seizure types

* Ligand earns $1.25 million milestone payment to be recognized in Q4

* Says approval milestone had been anticipated for Q3 and now will be recognized in Q4

* Lundbeck plans to make Carnexiv commercially available in United States in early 2017

* Is also entitled to receive a royalty of 2.75% on net sales of Carnexiv Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below